The Strategic Evolution of Antibody-Drug Conjugate Production Designing a therapeutic molecule that bridges the gap between precision biology and lethal chemistry requires an infrastructure that few global facilities can truly claim to possess. The biopharmaceutical landscape is currently
Defining a Target Product Profile early in the development cycle ensures that the manufacturing process is designed specifically to meet essential safety and efficacy attributes. In the high-stakes environment of 2026, biotechnology startups and academic spin-offs are often caught in a precarious
Italy’s export turnover for pharmaceutical contract manufacturing has quadrupled over the last decade, underscoring the sector's role as a cornerstone of the national economy. This remarkable trajectory has catapulted the nation to the forefront of the European Contract Development and
Industry leaders at the 8th Nigeria Pharma Manufacturers’ Expo are advocating for a two-year extension of the 2024 Executive Order to ensure long-term investment stability. Professor Mojisola Adeyeye, the Director-General of the National Agency for Food and Drug Administration and Control (NAFDAC),
The commissioning of the world’s first ConsiGma CDC Flex line in late 2027 marks a significant shift toward integrated, high-efficiency drug product manufacturing. This strategic thirty-five million dollar investment by Hovione at its East Windsor facility in New Jersey represents a major milestone
Fine chemical manufacturing traditionally depends on geographically concentrated resources that are increasingly sensitive to global supply chain disruptions. This vulnerability has prompted a massive re-evaluation of how the industrial sector approaches catalytic processes, which remain the
